$16.88
chg
0.00 (0.00%)
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
9.93
52 wk hi
34.3
Cash
$167.1M
Burn Rate (Qtr)
$47.2M
Mkt Cap
$785.4m
Avg Volume
3,950
*cash/burn updated:
Q1 '22
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Dasiglucagon
Congenital Hyperinsulinism
NDA
Submission
Exp Date
A free account is required to see the catalyst dates, notes, and more!
Glepaglutide
Short bowel syndrome
Phase 3
Interim Update
Exp Date
A free account is required to see the catalyst dates, notes, and more!
Dasiglucagon
Type 1 diabetes
Phase 3
Initiation
Exp Date
A free account is required to see the catalyst dates, notes, and more!
BI 456906 (GLP-1/glucagon dual agonist)
Obesity, Non-alcoholic steatohepatitis
Phase 2
Data readout
Exp Date
A free account is required to see the catalyst dates, notes, and more!
Dasiglucagon
Type 1 diabetes
Phase 2
Data readout
Exp Date
A free account is required to see the catalyst dates, notes, and more!
Loading Catalysts...
search in progress
Pipeline powered by
ZEAL
Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
Recent Posts
See what the community is saying - click to see full post.